Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine TumorGiuseppe Lamberti, Davide Campana, Antongiulio Faggiano et al.|The Journal of Clinical Endocrinology & Metabolism|2019Cited by 41
Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS groupAnnamaria Colao, Antongiulio Faggiano, Silvana Di Maio et al.|Endocrine|2019Cited by 35
Somatostatin Analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real lifeAntongiulio Faggiano, Annamaria Colao, Anna Chiara Carratù et al.|Oncotarget|2015Cited by 35
Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizationsFrancesco Panzuto, Davide Campana, Sara Pusceddu et al.|Pancreatology|2019Cited by 27
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national databaseFrancesco Panzuto, Massimo Falconi, Stefano Partelli et al.|Endocrine|2024Cited by 19